- Veliparib added to frontline induction chemotherapy and continued as single-agent maintenance therapy significantly improves PFS vs chemotherapy alone in advanced high-grade serous ovarian cancer.
Why this matters
- Together with data for niraparib, findings support PARP inhibitors as the new frontline standard of care.
- Multinational, phase 3 placebo-controlled double-blind trial of 1140 patients with advanced-stage high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Patients were randomly assigned 1:1:1 to chemotherapy-only (carboplatin+paclitaxel), veliparib+chemotherapy, or veliparib+chemotherapy with veliparib maintenance (veliparib-throughout).
- Funding: AbbVie.
- Median duration of follow-up was 28 months.
- Veliparib-throughout significantly improved median PFS vs chemotherapy-only in the:
- BRCA-mutation cohort (34.7 vs 22.0 months; HR, 0.44; P<.001>
- Homologous recombination deficiency cohort (31.9 vs 20.5 months; HR, 0.57; P<.001>
- Intent-to-treat population (23.5 vs 17.3 months; HR, 0.68; P<.001>
- Veliparib-throughout vs chemotherapy-only: neutropenia (58% vs 49%), anemia (38% vs 26%), thrombocytopenia (28% vs 8%), and leukopenia (18% vs 9%).
- Veliparib monotherapy: neutropenia (62%), anemia (41%), thrombocytopenia (31%), and leukopenia (12%).
- OS data were immature.